Source:
Regillo C. When to initiate therapy for proliferative diabetic retinopathy. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.
Disclosures:
Regillo reports having financial disclosures for 4D Molecular Therapeutics, Adverum, Alcon, Allergan, Annexon, Apellis, Astellas, Aviceda, Clearside Biomedical, Cognition Therapeutics, EyePoint Pharmaceuticals, Genentech, Gyroscope, Iveric Bio, Janssen, jCyte, Kodiak Sciences, Lineage Cell Therapeutics, Merck, NGM Bio, Notal Vision, Novartis, Ocugen, Ocular Therapeutix, Ocuphire Pharma, OcuTerra, Opthea, Ray, Regeneron, Regenxbio, Stealth BioTherapeutics, Théa and Zeiss.
Leave a Reply